Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature [0.03%]
免疫性血小板减少症患者的肠道微生态组成及失调的研究进展综述
Najmaldin Saki,Hakimeh Hadi,Bijan Keikhaei et al.
Najmaldin Saki et al.
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by excessive reticuloendothelial platelet destruction and inadequate compensatory platelet production. However, the pathogenesis of ITP is relatively complex, an...
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide [0.03%]
新型免疫治疗在多发性骨髓瘤引起的内皮损伤和功能障碍、COVID-19的影响以及以艾普司汀为代表的内皮保护作用
Clifton C Mo,Edward Richardson,Eleonora Calabretta et al.
Clifton C Mo et al.
Patients with multiple myeloma (MM) were among the groups impacted more severely by the COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality. MM and COVID-19, plus post-acute sequelae of SARS-CoV-2 infection...
Jorune Balciuniene,Yi Ning,Hillard M Lazarus et al.
Jorune Balciuniene et al.
Since the discovery of the Philadelphia chromosome in 1960, cytogenetic studies have been instrumental in detecting chromosomal abnormalities that can inform cancer diagnosis, treatment, and risk assessment efforts. The initial expansion of...
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria [0.03%]
因子B抑制剂 iptacopan治疗阵发性夜间血红蛋白尿症
Bo Xu,Bo Kang,Jixiang Chen et al.
Bo Xu et al.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated hemolytic anemia with a variety of manifestations. Currently, the methods for treating PNH include anti-C5 treatments (eculizumab and ravulizumab) and pegcetac...
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia [0.03%]
费城染色体阴性急性淋巴细胞白血病治疗进展
Madelyn Burkart,Shira Dinner
Madelyn Burkart
There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-t...
Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis [0.03%]
AL型淀粉样变性抗纤维蛋白治疗的现状与前景
Jinghua Wang,Jian Li,Liye Zhong
Jinghua Wang
Amyloid light-chain (AL) amyloidosis is a rare hematological disease that produces abnormal monoclonal immunoglobulin light chains to form amyloid fibrils that are deposited in tissues, resulting in organ damage and dysfunction. Advanced AL...
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review [0.03%]
外科和非外科手术后新发免疫介导的血栓性血小板减少性紫癜：系统评价
Morgana Pinheiro Maux Lessa,Alexandre Soares Ferreira Junior,Margaret Graton et al.
Morgana Pinheiro Maux Lessa et al.
When de-novo immune-mediated thrombotic thrombocytopenic purpura (TTP) is diagnosed following an invasive procedure, clinical presentation patterns and outcomes are poorly defined. Therefore, in a systematic literature review of patients di...
Meta-Analysis
Blood reviews. 2024 Jul:66:101197. DOI:10.1016/j.blre.2024.101197 2024
Yun Wang,Zhi-Jian Liang,Robert Peter Gale et al.
Yun Wang et al.
Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI s...
The acute pain crisis in sickle cell disease: What can be done to improve outcomes? [0.03%]
镰状细胞病的急性疼痛危象：如何才能改善预后？
Paul Telfer,Kofi A Anie,Stella Kotsiopoulou et al.
Paul Telfer et al.
The acute pain crisis (APC) is the commonest complication of sickle cell disease (SCD). Severe episodes may require treatment in hospital with strong opioid analgesic drugs, combined with additional supportive care measures. Guidelines for ...
BCL-2 inhibition in haematological malignancies: Clinical application and complications [0.03%]
BCL-2抑制在血液系统恶性肿瘤中的临床应用及并发症
Dominic J Fowler-Shorten,Charlotte Hellmich,Matthew Markham et al.
Dominic J Fowler-Shorten et al.
B-cell lymphoma-2 (BCL-2) family proteins are fundamental regulators of the intrinsic apoptotic pathway which modulate cellular fate. In many haematological malignancies, overexpression of anti-apoptotic factors (BCL-2, BCL-XL and MCL-1) ci...